AnalystBook Research · Company Intelligence

AbbVie Inc.

ABBVNYSE

Built from AbbVie Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data

AbbVie: Revenue grew 8.6% to $61.16B from $56.334B. Net income declined 1.2% to $4.226B from $4.278B. Free cash flow declined 0.1% to $17.816B from $17.832B. Operating margin expanded 843 bps to 24.65%. AbbVie's annual comparison also shows capital spending grew faster than revenue; inventory grew faster than revenue; the balance-sheet screen falls in the distress range and requires business-model context.

The read at a glance✓ Audited against SEC data
  • Growth — Revenue grew 8.6%OK
  • Profitability — Net income declined 1.2% to $4.226B from $4.278BWatch
  • Cash flow — Free cash flow declined 0.1% to $17.816B from $17.832BWatch
  • Margins — Operating margin expanded 843 bps to 24.65%OK
  • Accounting — Distress-range screen needs contextWatch
  • Insiders — 0 purchases and 5 salesNote

Business

AbbVie develops and markets medicines in immunology, oncology, neuroscience, aesthetics and other therapeutic areas.

Where the revenue comes from

Fiscal 2025, as AbbVie Inc. reports it. History and quarterly detail are in the app.

  • Immunology$30.4B
  • Neuroscience$10.8B
  • Oncology$6.7B
  • Aesthetics$4.9B
  • Other Key Products$3.7B

Leadership changes

From AbbVie Inc.'s own filings, the day they're filed.

  • Glenn F. Tilton · directors · departureeff. 2025-07-01
  • David R. Purdue · President · appointmenteff. 2025-03-01
  • Robert A. Michael · Chief Operating Officer · appointmenteff. 2023-06-29

Latest filings

  • 8-K · Company announcement2026-09-03
  • 8-K · Company announcement2026-08-18
  • 8-K · Company announcement2026-08-05
  • 10-Q · Quarterly report2026-08-03
  • 8-K · Company announcement2026-07-31
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about AbbVie Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full ABBV record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.